Elafibranor is a leading dual PPARα/δ agonist API and research compound at the forefront of metabolic disease drug discovery. With EC₅₀ values of 45 nM for PPARα and 175 nM for PPARδ , Elafibranor demonstrates potent activation of both targets, enabling comprehensive metabolic modulation. In research and development contexts, Elafibranor is supplied with comprehensive characterization data for preclinical studies, analytical method development, and quality control applications. The unique molecular architecture of Elafibranor enables selective PPAR activation with a favorable safety profile, making it a valuable tool for exploring the role of PPAR signaling in metabolic diseases. Elafibranor has been extensively studied in clinical trials for NASH, PBC, and primary sclerosing cholangitis , demonstrating its broad therapeutic potential.
|
Parameter |
Specification |
|
Product Name |
Elafibranor |
|
CAS Number |
824932-88-9 |
|
Molecular Formula |
C₂₂H₂₄O₄S |
|
Molecular Weight |
384.49 g/mol |
|
Appearance |
Yellow solid |
|
Density |
1.21 g/cm³ (predicted) |
|
Melting Point |
140-144 °C |
|
Boiling Point |
569.0 ± 50.0 °C |
|
Storage Condition |
Powder: –20°C (3 years); Solution: –80°C (1 year) |
Discovery success begins with purity. Elafibranor is a potent dual PPAR agonist — any impurity can compromise biological assay data and preclinical study results. Our analytical release protocol includes HPLC purity verification (≥98%), identity confirmation, and residual solvent analysis — because your research conclusions depend on the integrity of this compound.
Documentation that supports research integrity. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity data and chromatographic traceability.
Flexible supply across all research stages. Cosperpharm supplies Elafibranor from milligram quantities for screening to gram quantities for preclinical studies.
Technical support for metabolic research. Our scientific team can advise on formulation, solubility, and handling considerations for Elafibranor.
Global reach with transparent pricing. Cosperpharm ships worldwide with full customs documentation.
Clinical-Stage Compound
Elafibranor has been extensively evaluated in Phase 2 and Phase 3 clinical trials for NASH, PBC, and primary sclerosing cholangitis , demonstrating its therapeutic potential.
Favorable Safety Profile
Elafibranor does not activate PPARγ, avoiding the adverse cardiac effects associated with PPARγ agonists while maintaining metabolic efficacy .
High-Purity Research Compound
Cosperpharm supplies Elafibranor at ≥98% purity with full characterization data, suitable for in vitro and in vivo research applications.
Broad Therapeutic Potential
Elafibranor has shown promise in multiple metabolic disease indications, including NASH, PBC, primary sclerosing cholangitis, and type 2 diabetes .
Thorough analytical characterization. Each batch undergoes multi‑technique analytical release testing: HPLC purity (≥98%), appearance verification, and identity confirmation.
Full batch traceability. From synthesis through purification and final packaging, every step is fully documented and traceable.
Documentation ready for research use. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity data and identification information.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
